Blair William & Co. IL Purchases 32,925 Shares of Haleon PLC Sponsored ADR $HLN

Blair William & Co. IL grew its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 267.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,220 shares of the company's stock after purchasing an additional 32,925 shares during the quarter. Blair William & Co. IL's holdings in Haleon were worth $469,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Nuveen LLC acquired a new stake in shares of Haleon in the first quarter worth $58,870,000. Millennium Management LLC grew its stake in shares of Haleon by 697.2% in the first quarter. Millennium Management LLC now owns 4,216,504 shares of the company's stock worth $43,388,000 after acquiring an additional 3,687,613 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Haleon by 22.0% in the first quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company's stock worth $192,428,000 after acquiring an additional 3,372,155 shares during the last quarter. Sculptor Capital LP grew its stake in shares of Haleon by 22.1% in the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company's stock worth $111,645,000 after acquiring an additional 1,962,770 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Haleon by 933.1% in the first quarter. Jane Street Group LLC now owns 2,155,716 shares of the company's stock worth $22,182,000 after acquiring an additional 1,947,050 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HLN. Barclays downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Tuesday, September 16th. The Goldman Sachs Group upgraded shares of Haleon from a "neutral" rating to a "buy" rating in a research note on Wednesday, September 10th. Weiss Ratings restated a "hold (c)" rating on shares of Haleon in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Stock Performance

Haleon stock opened at $9.48 on Friday. The stock has a 50-day simple moving average of $9.41 and a 200 day simple moving average of $9.99. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The stock has a market capitalization of $42.22 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 2.69 and a beta of 0.20.

Haleon Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Shareholders of record on Friday, August 15th were issued a dividend of $0.0555 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a yield of 190.0%. This is an increase from Haleon's previous semi-annual dividend of $0.05. Haleon's dividend payout ratio (DPR) is presently 28.21%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.